The global Human Genetically Engineered Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Human Genetically Engineered Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Genetically Engineered Vaccine.
Report Scope
The Human Genetically Engineered Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Genetically Engineered Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Genetically Engineered Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Merck
GSK
Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
Walvax Biotechnology Co., Ltd.
Bharat Biotech
Chengdu Kanghua Biological Products Co., Ltd.
South China Vaccine Corporation Limited
Beijing Health Guard Biotechnology Inc.
CSL Limited
Emergent BioSolutions
Sanofi Pasteur
Serum Institute
Segment by Type
Genetic Recombinant Vaccine
Recombinant Subunit Vaccines
Genetic Vaccine
Segment by Application
Hepatitis E
Human Papillomavirus (HPV)
Rotavirus
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Genetically Engineered Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Genetically Engineered Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Human Genetically Engineered Vaccine 麻豆原创 Overview
1.1 Product Overview and Scope of Human Genetically Engineered Vaccine
1.2 Human Genetically Engineered Vaccine Segment by Type
1.2.1 Global Human Genetically Engineered Vaccine 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Genetic Recombinant Vaccine
1.2.3 Recombinant Subunit Vaccines
1.2.4 Genetic Vaccine
1.3 Human Genetically Engineered Vaccine Segment by Application
1.3.1 Global Human Genetically Engineered Vaccine 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hepatitis E
1.3.3 Human Papillomavirus (HPV)
1.3.4 Rotavirus
1.3.5 Others
1.4 Global Human Genetically Engineered Vaccine 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Human Genetically Engineered Vaccine Revenue 2019-2030
1.4.2 Global Human Genetically Engineered Vaccine Sales 2019-2030
1.4.3 Global Human Genetically Engineered Vaccine 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Genetically Engineered Vaccine 麻豆原创 Competition by Manufacturers
2.1 Global Human Genetically Engineered Vaccine Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Human Genetically Engineered Vaccine Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Human Genetically Engineered Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Human Genetically Engineered Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Genetically Engineered Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Genetically Engineered Vaccine, Product Type & Application
2.7 Human Genetically Engineered Vaccine 麻豆原创 Competitive Situation and Trends
2.7.1 Human Genetically Engineered Vaccine 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Genetically Engineered Vaccine Players 麻豆原创 Share by Revenue
2.7.3 Global Human Genetically Engineered Vaccine 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Genetically Engineered Vaccine Retrospective 麻豆原创 Scenario by Region
3.1 Global Human Genetically Engineered Vaccine 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Genetically Engineered Vaccine Global Human Genetically Engineered Vaccine Sales by Region: 2019-2030
3.2.1 Global Human Genetically Engineered Vaccine Sales by Region: 2019-2024
3.2.2 Global Human Genetically Engineered Vaccine Sales by Region: 2025-2030
3.3 Global Human Genetically Engineered Vaccine Global Human Genetically Engineered Vaccine Revenue by Region: 2019-2030
3.3.1 Global Human Genetically Engineered Vaccine Revenue by Region: 2019-2024
3.3.2 Global Human Genetically Engineered Vaccine Revenue by Region: 2025-2030
3.4 North America Human Genetically Engineered Vaccine 麻豆原创 Facts & Figures by Country
3.4.1 North America Human Genetically Engineered Vaccine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Genetically Engineered Vaccine Sales by Country (2019-2030)
3.4.3 North America Human Genetically Engineered Vaccine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Human Genetically Engineered Vaccine 麻豆原创 Facts & Figures by Country
3.5.1 Europe Human Genetically Engineered Vaccine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Genetically Engineered Vaccine Sales by Country (2019-2030)
3.5.3 Europe Human Genetically Engineered Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Genetically Engineered Vaccine 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Human Genetically Engineered Vaccine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Genetically Engineered Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Genetically Engineered Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Human Genetically Engineered Vaccine 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Human Genetically Engineered Vaccine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Genetically Engineered Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Human Genetically Engineered Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Genetically Engineered Vaccine 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Human Genetically Engineered Vaccine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Genetically Engineered Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Genetically Engineered Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Genetically Engineered Vaccine Sales by Type (2019-2030)
4.1.1 Global Human Genetically Engineered Vaccine Sales by Type (2019-2024)
4.1.2 Global Human Genetically Engineered Vaccine Sales by Type (2025-2030)
4.1.3 Global Human Genetically Engineered Vaccine Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Human Genetically Engineered Vaccine Revenue by Type (2019-2030)
4.2.1 Global Human Genetically Engineered Vaccine Revenue by Type (2019-2024)
4.2.2 Global Human Genetically Engineered Vaccine Revenue by Type (2025-2030)
4.2.3 Global Human Genetically Engineered Vaccine Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Human Genetically Engineered Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Genetically Engineered Vaccine Sales by Application (2019-2030)
5.1.1 Global Human Genetically Engineered Vaccine Sales by Application (2019-2024)
5.1.2 Global Human Genetically Engineered Vaccine Sales by Application (2025-2030)
5.1.3 Global Human Genetically Engineered Vaccine Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Human Genetically Engineered Vaccine Revenue by Application (2019-2030)
5.2.1 Global Human Genetically Engineered Vaccine Revenue by Application (2019-2024)
5.2.2 Global Human Genetically Engineered Vaccine Revenue by Application (2025-2030)
5.2.3 Global Human Genetically Engineered Vaccine Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Human Genetically Engineered Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer Human Genetically Engineered Vaccine Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merck Human Genetically Engineered Vaccine Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 GSK Human Genetically Engineered Vaccine Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
6.4.1 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Corporation Information
6.4.2 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Description and Business Overview
6.4.3 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Human Genetically Engineered Vaccine Product Portfolio
6.4.5 Beijing Wantai Biological Pharmacy Enterprise CO.,LTD. Recent Developments/Updates
6.5 Walvax Biotechnology Co., Ltd.
6.5.1 Walvax Biotechnology Co., Ltd. Corporation Information
6.5.2 Walvax Biotechnology Co., Ltd. Description and Business Overview
6.5.3 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Walvax Biotechnology Co., Ltd. Human Genetically Engineered Vaccine Product Portfolio
6.5.5 Walvax Biotechnology Co., Ltd. Recent Developments/Updates
6.6 Bharat Biotech
6.6.1 Bharat Biotech Corporation Information
6.6.2 Bharat Biotech Description and Business Overview
6.6.3 Bharat Biotech Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Bharat Biotech Human Genetically Engineered Vaccine Product Portfolio
6.6.5 Bharat Biotech Recent Developments/Updates
6.7 Chengdu Kanghua Biological Products Co., Ltd.
6.6.1 Chengdu Kanghua Biological Products Co., Ltd. Corporation Information
6.6.2 Chengdu Kanghua Biological Products Co., Ltd. Description and Business Overview
6.6.3 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Chengdu Kanghua Biological Products Co., Ltd. Human Genetically Engineered Vaccine Product Portfolio
6.7.5 Chengdu Kanghua Biological Products Co., Ltd. Recent Developments/Updates
6.8 South China Vaccine Corporation Limited
6.8.1 South China Vaccine Corporation Limited Corporation Information
6.8.2 South China Vaccine Corporation Limited Description and Business Overview
6.8.3 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 South China Vaccine Corporation Limited Human Genetically Engineered Vaccine Product Portfolio
6.8.5 South China Vaccine Corporation Limited Recent Developments/Updates
6.9 Beijing Health Guard Biotechnology Inc.
6.9.1 Beijing Health Guard Biotechnology Inc. Corporation Information
6.9.2 Beijing Health Guard Biotechnology Inc. Description and Business Overview
6.9.3 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Beijing Health Guard Biotechnology Inc. Human Genetically Engineered Vaccine Product Portfolio
6.9.5 Beijing Health Guard Biotechnology Inc. Recent Developments/Updates
6.10 CSL Limited
6.10.1 CSL Limited Corporation Information
6.10.2 CSL Limited Description and Business Overview
6.10.3 CSL Limited Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CSL Limited Human Genetically Engineered Vaccine Product Portfolio
6.10.5 CSL Limited Recent Developments/Updates
6.11 Emergent BioSolutions
6.11.1 Emergent BioSolutions Corporation Information
6.11.2 Emergent BioSolutions Human Genetically Engineered Vaccine Description and Business Overview
6.11.3 Emergent BioSolutions Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Emergent BioSolutions Human Genetically Engineered Vaccine Product Portfolio
6.11.5 Emergent BioSolutions Recent Developments/Updates
6.12 Sanofi Pasteur
6.12.1 Sanofi Pasteur Corporation Information
6.12.2 Sanofi Pasteur Human Genetically Engineered Vaccine Description and Business Overview
6.12.3 Sanofi Pasteur Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Sanofi Pasteur Human Genetically Engineered Vaccine Product Portfolio
6.12.5 Sanofi Pasteur Recent Developments/Updates
6.13 Serum Institute
6.13.1 Serum Institute Corporation Information
6.13.2 Serum Institute Human Genetically Engineered Vaccine Description and Business Overview
6.13.3 Serum Institute Human Genetically Engineered Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Serum Institute Human Genetically Engineered Vaccine Product Portfolio
6.13.5 Serum Institute Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Genetically Engineered Vaccine Industry Chain Analysis
7.2 Human Genetically Engineered Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Genetically Engineered Vaccine Production Mode & Process
7.4 Human Genetically Engineered Vaccine Sales and 麻豆原创ing
7.4.1 Human Genetically Engineered Vaccine Sales Channels
7.4.2 Human Genetically Engineered Vaccine Distributors
7.5 Human Genetically Engineered Vaccine Customers
8 Human Genetically Engineered Vaccine 麻豆原创 Dynamics
8.1 Human Genetically Engineered Vaccine Industry Trends
8.2 Human Genetically Engineered Vaccine 麻豆原创 Drivers
8.3 Human Genetically Engineered Vaccine 麻豆原创 Challenges
8.4 Human Genetically Engineered Vaccine 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Pfizer
Merck
GSK
Beijing Wantai Biological Pharmacy Enterprise CO.,LTD.
Walvax Biotechnology Co., Ltd.
Bharat Biotech
Chengdu Kanghua Biological Products Co., Ltd.
South China Vaccine Corporation Limited
Beijing Health Guard Biotechnology Inc.
CSL Limited
Emergent BioSolutions
Sanofi Pasteur
Serum Institute
听
听
*If Applicable.